Pharmacological management of non-specific chronic low back pain Ft. Dr. Raju Vaishya

Nonspecific chronic low back pain (NCLBP) is the single most common cause of pain and disability in industrialized countries and a common cause for consultation in primary care. The world population of adults aged 60 years or older is expected to double by 2050, and NCLBP might become a major public health burden worldwide. The prevalence of NCLPB in women is double compared to men.

A paper was recently published in the journal BMC Musculoskeletal Disorders titled 'Between guidelines and clinical trials: evidence-based advice on the pharmacological management of non-specific chronic low back pain' that looks at the management of NCLBP with various medications.

So to discuss this study in detail, Medical Dialogues interviewed one of the authors of the research paper Dr. (Prof) Raju Vaishya. Dr. (Prof) Raju Vaishya is a renowned Orthopedics and joint replacement surgeon having an experience of more than 35 years. He is currently a senior consultant at Indraprastha Apollo Hospital, New Delhi. His interest lies in Knee & Hip Surgery (Total Joint Replacement &; Arthroscopic Surgery), Regenerative therapy in orthopedics, Arthroscopic shoulder surgery, Arthritis & Osteoporosis, and research & publications. 

Reference:

Migliorini, F., Vaishya, R., Pappalardo, G. et al. Between guidelines and clinical trials: evidence-based advice on the pharmacological management of non-specific chronic low back pain. BMC Musculoskelet Disord 24, 432 (2023). https://doi.org/10.1186/s12891-023-06537-0